Bristol Myers Squibb Presents 56-Week Phase 3 Camzyos Data in Pediatric Patients with Obstructive Hypertrophic Cardiomyopathy at HCMS Scientific Sessions

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois. The SCOUT-HCM clinical trial evaluated the efficacy and safety of Camzyos (mavacamten) in pediatric patients aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). These additional data build upon confidence in Camzyos, whichhas the broadest indication of any cardiac myosin inhibitor (CMI) and is the first CMI approved for pediatric patients with symptomatic oHCM.

Results from the 56-week data are consistent with previously reported 28-week results from the trial. Bristol Myers Squibb will be sharing additional presentations that add to the breadth of clinical and real-world data supporting the use of Camzyos across patient populations, reinforcing the consistent efficacy and safety profile of Camzyos as a treatment for symptomatic oHCM, at the American Heart Association’s Scientific Sessions 2026 taking place November 6 – 9, 2026, in Chicago, Illinois.

–Bristol Myers Squibb (NYSE: BMY) today presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, taking place November 6, 2026, in Chicago, Illinois. The SCOUT-HCM clinical trial evaluated the efficacy and safety of Camzyos (mavacamten) in pediatric patients aged 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). These additional data build upon confidence in Camzyos, whichhas the broadest indication of any cardiac myosin inhibitor (CMI) and is the first CMI approved for pediatric patients with symptomatic oHCM. Results from the 56-week data are consistent with previously reported 28-week results from the trial. Bristol Myers Squibb will be sharing additional presentations that add to the breadth of clinical and real-world data supporting the use of Camzyos across patient populations, reinforcing the consistent efficacy and safety profile of Camzyos as a treatment for symptomatic oHCM, at the American Heart Association’s Scientific Sessions 2026 taking place November 6 – 9, 2026, in Chicago, Illinois.

SCOUT-HCM is a randomized, double-blind, placebo-controlled Phase 3 trial that evaluated Camzyos compared to placebo in pediatric patients aged 12 to <18 years old with symptomatic oHCM. Of the 44 randomized participants, 43 (mavacamten, n=23; placebo, n=20) completed the double-blind placebo-controlled period and entered the active treatment period. At week 28, all 43 patients who completed the double-blind placebo-controlled period were assigned Camzyos through week 56. Patients across both trial arms (mavacamten–mavacamten and placebo-mavacamten)achieved significant reductions in Valsalva left ventricular outflow tract (LVOT) gradient. Patients in the mavacamten–mavacamten arm experienced a mean change from baseline of -48.1 mmHg after 56 weeks of treatment. A similar degree of gradient reduction was observed in the placebo group after switching to mavacamten. Patients in both studyarmsshowed meaningful improvements in several secondary endpoints, with no new safety signals reported.

Camzyos demonstrated a safety profile that was consistent with previously reported results for the SCOUT-HCM clinical trial, as well as previously reported Phase 3 studies evaluating Camzyos in an adult population. Treatment-related treatment-emergent adverse events (TEAEs) and serious TEAEs were low, with five and two events, respectively, reported in the mavacamten–mavacamten arm over 56 weeks of treatment, and one and zero events, respectively, reported in the placebo-mavacamtenarm over 28 weeks of treatment. Over the 56-week period, no patient in the trial had experienced left ventricular ejection fraction (LVEF) <50%.

Symptomatic oHCM is a serious condition for which having effective and safe treatments is crucial. These additional SCOUT-HCM results provide added confidence in Camzyos to healthcare providers as they consider treatment options for their pediatric patients with oHCM,” said Cristian Massacesi, MD, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “BMS is committed to researching and developing new treatments to address cardiovascular disease. The data presented at these congresses helps us better understand symptomatic oHCM and the role of Camzyos in delivering more meaningful outcomes for patients and their families.”

Additional presentations at the American Heart Association’s Scientific Sessions add to the growing body of evidence supporting the efficacy and safety profile for Camzyos as a treatment option for adult patients with symptomatic oHCM. Two presentations build upon the evidence demonstrating the effectiveness and safety profile of Camzyos with long-term use. Data presented from the Camzyos Risk Evaluation and Mitigation Strategy (REMS) program after four years of follow up showed safety findings consistent with those observed in clinical trials. In a cardiac magnetic resonance (CMR) analysis of the EXPLORER cohort of the MAVA-LTE study, favorable changes in measures of cardiac structure and function were observed over up to five years of follow-up. An analysis of the EXPLORER-HCM study evaluating the impact of Camzyos treatment on a proteomic cardiovascular (CV) risk score, which has previously been reported to predict cardiovascular risk over 4 years, showed that Camzyos reduced the CV Risk SomaSignal® Test (SST) score in adult patients with oHCM. An analysis of MARVEL-HCM provided real-world insights on the impact of Camzyos use stratified by sarcomere gene variant status, with effectiveness and safety results that were consistent across variant-positive and variant-negative subgroups.

Camzyos was approved for the treatment of pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM to improve functional capacity and symptoms by the U.S. Food and Drug Administration (FDA) in September 2026. The FDA approval was based on positive 28-week results from the Phase 3 SCOUT-HCM clinical trial. Camzyos was first approved by the FDA in 2022 for the treatment of adults with symptomatic NYHA class II-III oHCM. Camzyos is supported by the largest body of worldwide evidence in the CMI treatment class.

About the Phase 3 SCOUT-HCM Trial1,2,3

SCOUT-HCM (NCT06253221) is a Phase 3 randomized, double-blind, placebo-controlled, international trial that enrolled 44 pediatric patients (12 years to <18 years old) with symptomatic oHCM. The trial includes three treatment periods totaling up to 200 weeks: a 28-week placebo-controlled period, followed by a 28-week active-treatment period (when patients randomized to placebo cross over to Camzyos), and an open-label long-term extension period for up to 144 weeks. At baseline, 83% and 86% of patients were receiving beta blockers, 13% and 10% were receiving calcium channel blockers, and 17% and 24% were receiving disopyramide, in the Camzyos and placebo groups, respectively. Mean LVEF was 69.0% in the Camzyos group and 67.4% in the placebo group; mean Valsalva LVOT gradient was 78 mmHg in the Camzyos group and 81 mmHg in the placebo group. Patients were randomized in a 1:1 ratio and administered either Camzyos, starting dose of 2.5 mg Camzyos for body weight 35 to <45 kg, 5 mg Camzyos for body weight ≥45 kg, or placebo, once daily for 28 weeks. Dose adjustment was based on clinical echocardiogram parameters.

The primary endpoint was change from baseline to Week 28 in Valsalva LVOT gradient (mmHg). Secondary endpoints (descriptive only) included change from baseline to Week 28 in efficacy parameters of resting and postexercise LVOT gradients, peak oxygen consumption (proportion of patients achieving an increase from baseline in pVO2), symptoms (proportion of patients with at least 1 NYHA Class improvement) and HCM Symptom Questionnaire Shortness of Breath domain (HCMSQ SoB), plus safety and pharmacokinetic parameters.

Source link

Share your love